Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been given an average rating of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $16.88.

Several equities analysts have recently commented on the stock. Guggenheim upped their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

Several institutional investors have recently modified their holdings of the company. OLD Second National Bank of Aurora acquired a new stake in Amicus Therapeutics in the third quarter valued at $26,000. Hazlett Burt & Watson Inc. raised its position in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,569 shares in the last quarter. Blue Trust Inc. lifted its stake in Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new position in Amicus Therapeutics in the third quarter valued at approximately $32,000. Finally, Covestor Ltd increased its stake in Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 2,312 shares during the last quarter.

Amicus Therapeutics Trading Up 1.3 %

NASDAQ FOLD opened at $9.77 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The stock has a market capitalization of $2.92 billion, a P/E ratio of -28.74, a PEG ratio of 1.69 and a beta of 0.61. The firm’s 50-day moving average is $9.60 and its two-hundred day moving average is $10.43. Amicus Therapeutics has a 12 month low of $8.78 and a 12 month high of $14.03.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.